AU708123B2 — Matrix type patch formulation
Assigned to Hisamitsu Pharmaceutical Co Inc · Expires 1999-07-29 · 27y expired
What this patent protects
A matrix type patch formulation which comprises an adhesive layer containing a physiological active substance, an organic acid, a hydrophobic high molecular material, a tackifying resin, a plasticizer and an absorption enhancer, is disclosed. The adhesive layer preferably contain…
USPTO Abstract
A matrix type patch formulation which comprises an adhesive layer containing a physiological active substance, an organic acid, a hydrophobic high molecular material, a tackifying resin, a plasticizer and an absorption enhancer, is disclosed. The adhesive layer preferably contains 0.1 to 20 %(w/w) of the physiological active substance, 0.01 to 15 %(w/w) of the organic acid, 15 to 60 %(w/w) of the hydrophobic high molecular material, 10 to 70 %(w/w) of the tackifying resin, 10 to 60 %(w/w) of the plasticizer and 0.01 to 20 %(w/w) of the absorption enhancer. The organic acid is preferably an aliphatic carboxylic acid, an aromatic carboxylic acid, an alkyl sulfonic acid, an alkyl sulfonic acid derivative, cholic acid derivative or a water-soluble inorganic salt thereof. The matrix type patch formulation of the present invention can increase the percutaneous absorbability of the physiological active substance and is extremely reduced in skin irritation.
Drugs covered by this patent
- Aldara (IMIQUIMOD) · Bausch Health
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.